Trial · NCT07262983
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of SAEs, AEs requiring study drug discontinuation. | Through end of study | To determine the safety and tolerability of JAK inhibitor treatment (baricitinib) in patients with Job s syndrome with lupus-like disease and/or AD. |
| Secondary | Incidence of Candida and/or bacterial infections. | Through end of study | To assess changes in Candida and/or bacterial infections |
| Secondary | Mean change in CLASI score from day -90 to day 0 and then from day 0 to days 90 and 180. | From day -90 to day 0 and then from day 0 to days 90 and 180 | To evaluate the effect of baricitinib on lupus-like features. |
| Secondary | Mean change in EASI score from day -90 to day 0 and then from day 0 to days 90 and 180. | From day -90 to day 0 and then from day 0 to days 90 and 180 | To evaluate the effect of baricitinib on AD. |
| Secondary | Mean change in SLEDAI score from day -90 to day 0 and then from day 0 to days 90 and 180. | From day -90 to day 0 and then from day 0 to days 90 and 180 | To evaluate the effect of baricitinib on lupus-like features. |
| Secondary | Mean change in the PGA score from day -90 to day 0 and then from day 0 to days 90 and 180. | From day -90 to day 0 and then from day 0 to days 90 and 180 | To evaluate the effect of baricitinib on lupus-like features and AD. |
| Secondary | Mean change in the SF-36 score (adults) from day -90 to day 0 and then from day 0 to days 90 and 180. | From day -90 to day 0 and then from day 0 to days 90 and 180 | To investigate the effect of baricitinib on QOL. |
| Secondary | Mean change in the PROMIS score from day -90 to day 0 and then from day 0 to days 90 and 180. | From day -90 to day 0 and then from day 0 to days 90 and 180 | To investigate the effect of baricitinib on QOL. |
| Secondary | Mean change in the DLQI score (adults) from day -90 to day 0 and then from day 0 to days 90 and 180. | From day -90 to day 0 and then from day 0 to days 90 and 180 | To investigate the effect of baricitinib on QOL. |
| Secondary | Mean change in the CDLQI score (pediatrics) from day -90 to day 0 and then from day 0 to days 90 and 180. | From day -90 to day 0 and then from day 0 to days 90 and 180 | To investigate the effect of baricitinib on QOL. |
| Secondary | Mean change in the PedsQL score (pediatrics) from day -90 to day 0 and then from day 0 to days 90 and 180. | From day -90 to day 0 and then from day 0 to days 90 and 180 | To investigate the effect of baricitinib on QOL. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07262983/registered